SCHEMBL3541014

SCHEMBL3541014

CNn1ccc(=O)[nH]c1=O

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 4/20 0.54
DDB1 Q16531 1/20 0.44
PKM P14618 1/20 0.40
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
DUT P33316 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181554 0.78 CRBN (0.54) CRBNDDB1PKMALDH1A1LMNA
SCHEMBL8933239 0.76 CRBN (0.47) CRBNDDB1PKMALDH1A1LMNA
SCHEMBL30479438 0.76 CRBN (0.47) CRBNDDB1PKMALDH1A1LMNA
SCHEMBL11389897 0.75 CRBN (0.46) CRBNDDB1PKMALDH1A1LMNA
SCHEMBL9019445 0.74 CRBN (0.44) CRBNDDB1ALDH1A1LMNADUT
SCHEMBL29138724 0.74 CRBN (0.44) CRBNDDB1PKMALDH1A1LMNA
SCHEMBL7030201 0.72 CRBN (0.43) CRBNDDB1PKMALDH1A1LMNA
SCHEMBL28414334 0.72 CRBN (0.47) CRBNDDB1ALDH1A1LMNADUT
SCHEMBL12099167 0.71 CRBN (0.42) CRBNDDB1PKMALDH1A1LMNA
SCHEMBL9763767 0.71 CRBN (0.42) CRBNPKMDUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200362337-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2020-11-19 US disclosed
US-9856230-B2 Enzyme inhibitors UNIVERSITY OF SUNDERLAND (GB) 2018-01-02 US disclosed
US-20150322035-A1 Enzyme Inhibitors UNIVERSITY OF SUNDERLAND (GB) 2015-11-12 US disclosed
CN-101003512-B Method for preparing methylamino uracil SHANGHAI CHEMICAL REAGENT RES INST 2011-03-16 CN disclosed
US-7709471-B2 Compounds ASTRAZENECA AB (SE) 2010-05-04 US disclosed
EP-2046793-A2 FUSED PYRIMIDO COMPOUNDS AstraZeneca AB (SE) 2009-04-15 EP disclosed
WO-2008003958-A2 FUSED PYRIMIDO COMPOUNDS ASTRAZENECA AB (SE) 2008-01-10 WO disclosed
US-20080009482-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2008-01-10 US disclosed
CN-101003512-A Method for preparing methylamino uracil SHANGHAI INST OF CHEMICAL AGEN (CN) 2007-07-25 CN disclosed
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives 4 AZA BIOSCIENCE NV (BE) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322035-A1 Enzyme Inhibitors TXNRD3, TXNRD2, TXNRD1 CRBN 2179/4885DDB1 1254/4885PKM 1247/4885
US-20070043000-A1 Immunosuppresive effects of pteridine derivatives TPMT, FKBP5, RRP15 CRBN 2691/4885DDB1 896/4885PKM 892/4885
US-20080009482-A1 NOVEL COMPOUNDS CYP11B2, CYP11B1, CYP46A1 CRBN 3578/4885DDB1 4446/4885PKM 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.